Cardiovascular News

29/10/2024

ESC 2024: RESHAPE-HF2 results move conversation forward on effectiveness of TEER in functional MR

The trial’s principal investigator, Stefan Anker (Charite University Hospital, Berlin, Germany) said the findings should provide reassurance about the benefits of TEER using the MitraClip device (Abbott) in patients with moderate to severe functional MR and heart failure and could strengthen and broaden recommendations for its future use. Critics, however, are less enthusiastic about the conclusions.

Watch the full interview here:

A strategy of mitral transcatheter edge-to-edge repair (TEER) plus medical therapy in patients with heart failure and moderate to severe mitral regurgitation (MR), who were not eligible for surgery, was found to be more effective than optimal medical therapy alone, investigators in the RESHAPE-HF2 t...

23/04/2024

Are you part of the ? Secure your front-row seat to the future of valvular and structural heart disease at . Act now for an exclusive Heart Team Discount! Save up to 40% when you attend with your team! https://nyvalves2024.crfconferences.com/heart-team-discount

03/04/2024

Michael Reardon and Lars Søndergaard pay tribute to the life and legacy of Alain Cribier—the pioneer of transcatheter aortic valve implantation (TAVI) who died in February at the age of 79.

Reardon and Søndergaard discuss the world-changing impact of Cribier’s work, including how TAVI has revolutionised the treatment of aortic disease, and their recollections of him as an academic and human being.

Cribier who had been the director of cardiology at Charles Nicolle Hospital, University of Rouen (Rouen, France), was recognised globally for his role in the world’s first TAVI procedure in 2002.

Michael Reardon and Lars Søndergaard pay tribute to the life and legacy of Alain Cribier—the pioneer of transcatheter aortic valve implantation (TAVI) who died in February at the age of 79. Reardon and Søndergaard discuss the world-changing impact of Cribier’s work, including how TAVI has revo...

07/12/2023

With an expected rise in redo TAVI and valve-in-valve procedures, there is heightened interest in technologies that can help to facilitate coronary access and prevent obstruction resulting from the treatment.

At PCR London Valves, Didier Tchetche presented details of the ShortCut pivotal trial, outlining details of one such device aimed at addressing this need.

Details of the first pivotal trial assessing the use of a dedicated leaflet splitting device to facilitate future coronary access in patients undergoing transcatheter aortic valve implantation (TAVI) who may be at risk of valve-in-valve induced coronary obstruction were shared at PCR London Valves (...

06/10/2023

Sponsored: Join us at EACTS in Vienna for a lunch symposium on mitral valve replacement with Prof Jose Luis Pomar and Prof Jörg Kempfert, with a particular emphasis on patient selection, outcomes derived from the literature, and the most recent technological advancements in this field.

05/10/2023

Join Edwards Lifesciences at EACTS in Vienna for a lunch symposium on RESILIA tissue presented by Prof. Bavaria and Prof. Grabenwöger, where they will present an extensive collection of clinical data as well as conducting a data comparison within the Carpentier-Edwards PERIMOUNT platform.

26/07/2023

Interventional cardiologists need to have a range of approaches and devices in their toolbox to treat the increasingly complex patient population entering the cath lab. Key among them, Victor Jimenez (Vigo, Spain) tells Cardiovascular News, are drug-coated balloons (DCBs), which can be used in a range of clinical scenarios in a DCB-only percutaneous coronary intervention (PCI) approach, or alongside drug-eluting stents (DESs) as part of a hybrid PCI strategy.

Jimenez notes that there is no class effect with DCBs. Therefore, their clinical results should be evaluated in specific clinical studies for each particular device. The availability of DCBs backed by a strong body of evidence to demonstrate both safety and efficacy, such as the SeQuent® DCB family of devices, is changing the way that interventional cardiologists think about tackling coronary artery disease, and more physicians will look towards a DCB-first strategy in the future, Jimenez comments, as they seek to avoid implanting a metallic scaffold in the coronary arteries.

“DCBs and stents are complementary devices and not the opposite,” he says in this interview, in which he discusses how DCBs can address some of the limitations of DES platforms, the clinical scenarios in which balloons are favourable, and how the DCB fits into the modern cardiology toolbox.

This video is sponsored by B Braun Melsungen AG.

Watch the full video here: https://cardiovascularnews.com/latest-generation-dcbs-change-thinking-on-treatment-of-coronary-artery-disease/

Interventional cardiologists need to have a range of approaches and devices in their toolbox to treat the increasingly complex patient population entering the cath lab.

08/06/2023

STEMI patients “lose years of life” due to care delays during COVID-19 lockdowns, new research suggests

Patients with ST-elevation myocardial infarction (STEMI) occurring during the first COVID-19 lockdown in the UK and Spain are predicted to live 1.5 and two years less, respectively, than their pre-COVID counterparts.

08/06/2023

Read the second part of our series on TAVI related stroke where we explore why stroke matters for TAVI patients, sponsored by Boston Scientific and featuring contributions from Prof Ole de Backer & Dr Vlasis Ninios

Stroke—particularly disabling stroke—is among the major potential complications of a transcatheter aortic valve implantation (TAVI) procedure.

07/06/2023

Are drug-coated balloons ready for the primetime in PCI?

In this advertorial, sponsored by B Braun Melsungen AG, Marie-Claude Morice discusses the growing interest in the use of DCBs in coronary interventions, and considers what's next for the technology.

Read more here:

“The evolution of PCI has always been a continuum, with new devices addressing the limitations of previous devices,” Marie-Claude Morice tells Cardiovascular News of the growing interest in DCBs in coronary interventions.

07/06/2023

SPONSORED: Great just got better! Explore our latest and most deliverable drug eluting stent³: Onyx Frontier DES.

Learn more ➡ https://lnkd.in/d7BSQW4p

11/04/2023

Sponsored: Naviscore is iVascular's innovative coronary scoring balloon that breaks new ground by combining the benefits of scoring and cutting balloons. Learn more about this new player for calcified lesions here: https://ivascular.global/therapeutic-areas/coronary/naviscore/